Apixaban (Eliquis) and rivaroxaban (Xarelto) are commonly used in patients with atrial fibrillation and valvular heart disease, but comparative data is limited. New study compares the risks of stroke, systemic embolism and bleeding events.

Resources:

https://www.eurekalert.org/news-releases/968352

https://www.acpjournals.org/doi/10.7326/M22-0318